Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma

被引:33
作者
Addo-Yobo, Steven O.
Straessle, Jennifer
Anwar, Adil
Donson, Andrew M.
Kleinschmidt-DeMasters, B. K.
Foreman, Nicholas K.
机构
[1] Denver Childrens Hosp, Denver, CO USA
[2] Univ Colarado Denver & Hlth Sci, Dept Pediat & Pathol, Aurora, CO 80045 USA
[3] Univ Colarado Denver & Hlth Sci, Dept Neurol & Neurosurg, Aurora, CO 80045 USA
关键词
pilocytic astrocytoma; ErbB3; Sox10; developmental genes; gefitinib;
D O I
10.1097/01.jnen.0000229989.25171.aa
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Pilocytic astrocytoma (PA) is the most common glioma of childhood. Despite their relatively high incidence, the molecular mechanisms responsible for tumorigenesis and growth of PA are poorly understood. Previous in vitro studies in our laboratory showed that despite the absence of ErbB1, PA was sensitive to ErbB1 tyrosine kinase inhibitor gefitinib. To identify alternative targets of gefitinib in PA, we studied other members of the ErbB receptor tyrosine kinase family that have been identified in brain tumors. Using gene expression microarray and Western blot analyses, we found that ErbB3 is highly overexpressed in PA compared with other pediatric brain tumors (glioblastoma, ependymoma, medulloblastoma, atypical teratoid/rhabdoid tumor, and choroid plexus papilloma). Developmental biology studies have identified Sox10 as a regulator of ErbB3 expression during development of the neural crest. Investigation of Sox10 in PA revealed that it is highly overexpressed relative to other pediatric brain tumors, lending support to the theory that Sox10-regulated overexpression of ErbB3 may be driving growth in PA. Sox10-regulated ErbB3 overexpression is a novel insight into the biology of PA, suggests possible recapitulation of developmental pathways in tumorigenesis, and presents possible targets for therapeutic intervention that might be used for hypothalamic variants not amenable to surgical cure.
引用
收藏
页码:769 / 775
页数:7
相关论文
共 30 条
[1]  
Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO
[2]  
2-2
[3]   Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas [J].
Andersson, U ;
Guo, D ;
Malmer, B ;
Bergenheim, AT ;
Brännström, T ;
Hedman, H ;
Henriksson, R .
ACTA NEUROPATHOLOGICA, 2004, 108 (02) :135-142
[4]   Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas [J].
Bannykh, SI ;
Stolt, CC ;
Kim, J ;
Perry, A ;
Wegner, M .
JOURNAL OF NEURO-ONCOLOGY, 2006, 76 (02) :115-127
[5]   An anatomy of normal and malignant gene expression [J].
Boon, K ;
Osório, EC ;
Greenhut, SF ;
Schaefer, CF ;
Shoemaker, J ;
Polyak, K ;
Morin, PJ ;
Buetow, KH ;
Strausberg, RL ;
de Souza, SJ ;
Riggins, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) :11287-11292
[6]   The transcription factor Sox10 is a key regulator of peripheral glial development [J].
Britsch, S ;
Goerich, DE ;
Riethmacher, D ;
Peirano, RI ;
Rossner, M ;
Nave, KA ;
Birchmeier, C ;
Wegner, M .
GENES & DEVELOPMENT, 2001, 15 (01) :66-78
[7]   Neuregulin and ErbB receptor signaling pathways in the nervous system [J].
Buonanno, A ;
Fischbach, GD .
CURRENT OPINION IN NEUROBIOLOGY, 2001, 11 (03) :287-296
[8]  
Burger PC, 2000, PATHOLOGY GENETICS T, P45
[9]   Neuregulin and erbB receptor expression in normal and diseased human white matter [J].
Cannella, B ;
Pitt, D ;
Marchionni, M ;
Raine, CS .
JOURNAL OF NEUROIMMUNOLOGY, 1999, 100 (1-2) :233-242
[10]   HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients [J].
Cappuzzo, F ;
Toschi, L ;
Domenichini, I ;
Bartolini, S ;
Ceresoli, GL ;
Rossi, E ;
Ludovini, V ;
Cancellieri, A ;
Magrini, E ;
Bemis, L ;
Franklin, WA ;
Crino, L ;
Bunn, PA ;
Hirsch, FR ;
Varella-Garcia, M .
BRITISH JOURNAL OF CANCER, 2005, 93 (12) :1334-1340